FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants HOUSTON, June 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company...
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants HOUSTON, June 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.